Article Text

Download PDFPDF
1265 Ovarian sertoli-leydig tumor: a tricky tumor. Case report and review of the literature
  1. Chadia Khalloufi,
  2. Aya Kanas,
  3. Youness Benchrifi,
  4. Mustapha Benhessou,
  5. Mohammed Ennachit and
  6. Mohammed Elkerroumi
  1. Ibn Rochd Hospital, Casablanca, Morocco


Introduction/Background Ovarian Sertoli-Leydig cell tumors (SLCT) are a rare sex cord-stromal tumors, accounting for less than 0,2% of all ovarian malignancies. As these tumors are found at an early stage in young women, the whole management dilemma is finding the right balance between a treatment efficient enough to prevent recurrences but that still enables fertility-sparing.

Methodology It is a case study.

Results We report the case of a 17 years old patient hospitalized in the oncology and gynecology ward of the university hospital Ibn Rochd in Casablanca, presenting a moderately differentiated Sertoli-Leydig cell tumor in the right ovary, our aim is to analyze the clinical, radiological and histological characteristics of this rare tumor that can be tricky to diagnose and review the different management therapies available and the challenges they present.

Clinical discussion Ovarian Sertoli-Leydig cell tumors (SLCT) are a rare sex cord-stromal tumors that should not be misdiagnosed. The prognosis of patients with grade 1 SLCT is excellent without adjuvant chemotherapy. Intermediate and poorly differentiated SLCTs require more aggressive management. Complete surgical staging and adjuvant chemotherapy should be considered.

Conclusion Our case reaffirms that in the presence of a pelvic tumor syndrome and signs of virilization, SLCT should be suspected. The treatment is essentially surgical, if diagnosed early on, we can offer an effective treatment that preserves their fertility. Efforts should be focused on the creation of regional and international registries of SLCT cases in order to achieve greater statistical power in future studies.

Disclosures No conflict of interests.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.